novo nordisk news - Search News

Novo Nordisk upgraded to Buy from Neutral at UBS

Investopedia on MSN · 1d

Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone.

Business Insider · 1d

Novo Nordisk upgraded to Buy from Neutral at UBS, as CagriSema selloff overdone

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed”

Fintel on MSN · 1d

UBS Upgrades Novo Nordisk A (NVO)

Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. Analyst Price Forecast Suggests 61.15% Upside As of December 23, 2024, the average one-year price target for Novo Nordisk A is $137.

Novo Nordisk Expands AI Partnership With Valo Health

MarketWatch on MSN · 1d

Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug.

Seeking Alpha on MSN · 1d

Novo Nordisk, Valo Health expand drug discovery deal

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read more here.

U.S. News & World Report · 1d

Novo Nordisk Expands AI Partnership With Valo Health for Development of Obesity Drugs

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).

1don MSN

5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

12hon MSN

Novo, Eli Lilly to dominate global pharma sales in 2025: report

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

FierceBiotech1d

Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...

DPA International on MSN1d

Novo Nordisk expands drug collaboration with Valo Health

Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop ...

Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

1d

Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

5d

Better Buy: Novo Nordisk vs. AstraZeneca

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

2don MSN

Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results